Spartan Bioscience Building Evidence for Point-of-Care PGx Testing to Guide Antiplatelet Therapy | GenomeWeb

Originally published March 12.

SAN FRANCISCO – Using a point-of-care genetic test developed by Spartan Bioscience, Canadian researchers have demonstrated that rapid access to genetic test results for cardiac patients who have undergone a stent procedure allows doctors to identify early those at heightened risk of a major cardiac event and then personalize treatment with an antiplatelet drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.